NOVELLO, Silvia

NOVELLO, Silvia  

ONCOLOGIA  

Mostra records
Risultati 1 - 20 di 425 (tempo di esecuzione: 0.017 secondi).
Titolo Data di pubblicazione Autore(i) File
"Bad luck" or "science"? This is the dilemma [Article@"Bad luck" or "science"? This is the dylemma] 2015 Novello, S.
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 2020 Polverari, Giulia; Ceci, Francesco; Bertaglia, Valentina; Reale, Maria Lucia; Rampado, Osvaldo; Gallio, Elena; Passera, Roberto; Liberini, Virginia; Scapoli, Paola; Arena, Vincenzo; Racca, Manuela; Veltri, Andrea; Novello, Silvia; Deandreis, Désirée
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 2015 Eberhardt W.E.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S., Kerr K., Besse B., Vansteenkiste J., Edelman M., Mok T., O'Byrne K., Novello, S., Bubendorf L., Marchetti A., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit E.F., Meldgaard P., Adjei A., Nicolson M., Crinò L., Van Schil P., Senan S., Faivre-Finn C., Rocco G., Veronesi G., Douillard J.-Y., Lim E., Dooms C.
[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.] 2021 Esposito, Immacolata; Calabria, Silvia; Piccinni, Carlo; Addesi, Alice; Dondi, Letizia; Ronconi, Giulia; Pedrini, Antonella; Maggioni, Aldo Pietro; Curigliano, Giuseppe; Listi, Angela; Righi, Luisella; Novello, Silvia; Buglioni, Simonetta; Ciliberto, Gennaro; Pruneri, Giancarlo; Martini, Nello
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics 2019 Ferrer, Léonie; Giaj Levra, Matteo; Brevet, Marie; Antoine, Martine; Mazieres, Julien; Rossi, Giulio; Chiari, Rita; Westeel, Virginie; Poudenx, Michel; Letreut, Jacques; Gervais, Radj; Osman, Giorgia; Girard, Nicolas; Toffart, Anne Claire; Novello, Silvia; Moro-Sibilot, Denis*
A challenge to overcome: the maintenance of the global quality of life in patients with advanced or metastatic non-small cell lung cancer 2016 Silvia Novello; Simona Carnio
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 2014 Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design 2020 Passiglia F.; Bironzo P.; Righi L.; Listi A.; Arizio F.; Novello S.; Volante M.; Scagliotti G.V.
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. 2006 CAPPUZZO F ;NOVELLO S ;DE MARINIS F ;SELVAGGI G ;SCAGLIOTTI GV ;BARBIERI F ;MAUR M ;PAPI M ;PASQUINI E ;BARTOLINI S ;MARINI L ;CRINÒ L
A RANDOMIZED PHASE III TRIAL COMPARING STANDARD AND HIGH-DOSE PEMETREXED AS SECOND-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER. 2008 CULLEN MH; ZATLOUKAL P; SÖRENSON S; S. NOVELLO; FISCHER JR; JOY AA; ZEREU M; PETERSON P; VISSEREN-GRUL CM; ISCOE N
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 2022 Tagliamento M.; Bironzo P.; Curcio H.; De Luca E.; Pignataro D.; Rapetti S.G.; Audisio M.; Bertaglia V.; Paratore C.; Bungaro M.; Olmetto E.; Artusio E.; Reale M.L.; Zichi C.; Capelletto E.; Carnio S.; Buffoni L.; Passiglia F.; Novello S.; Scagliotti G.V.; Di Maio M.
A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomised trial. 2000 RINALDI M; CRINÒ L; SCAGLIOTTI GV; MOSCONI AM; DEMARINIS F; GRIDELLI C; SELVAGGI G; DELLA GIULIA M; DARWISH S; PORROZZI S; S. NOVELLO; CIPRI A; BARTOLUCCI R; CALANDRI C; TONATO M
Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield 2007 PRIOLA A.M; PRIOLA S.M; CATALDI A; ERRICO L; DI FRANCO M; CAMPISI P; MOLINARO L; MARCI V; NOVELLO S; C. FAVA
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINEVINORELBINE IN ADVANCED NON SMALL CELL LUNG CANCER ELDERLY PATIENTS. PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY MILES RANDOMISED TRIAL. 2001 GRIDELLI C; CIGOLARI S; GALLO C; MANZIONE L; IANNELLO GP; FRONTINI L; FERRAÙ F; S. NOVELLO; PERRONE F; ON BEHALF OF THE MILES INVESTIGATORS
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 2014 Landi L;Tiseo M;Chiari R;Ricciardi S;Rossi E;Galetta D;Novello S;Milella M;D'Incecco A;Minuti G;Tibaldi C;Salvini J;Facchinetti F;Haspinger ER;Cortinovis D;Santo A;Banna G;Catino A;GiajLevra M;Crinò L;de Marinis F;Cappuzzo F
Actuality and perspective in the medical treatment of non-small cell lung cancer [Article@Attualità e prospettive nella terapia medica del carcinoma polmonare non-a piccole cellule] 2012 Levra, M.G., Novello, S.
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 2015 Barni, Sandro; Maiello, Evaristo; Di Maio, Massimo; Ardizzoni, Andrea; Cappuzzo, Federico; Maranzano, Ernesto; Novello, Silvia; Bennati, Chiara; Ori, Alessandra; Rizzoli, Sara; Crinò, Lucio
Adjuvant chemotherapy after complete resection for early stage NSCLC 2003 SCAGLIOTTI G ;NOVELLO S
Adjuvant chemotherapy in completely resected Non-small cel lung cancer. 2005 GIORGIO V. SCAGLIOTTI; S. NOVELLO; AND VALTER TORRI
Adjuvant chemotherapy in completely resected Non-Small Cell Lung Cancer, cap 32 2005 GIORGIO V. SCAGLIOTTI; S. NOVELLO; AND VALTER TORRI